Amyotrophic Lateral Sclerosis (ALS) Panel

This program, offered in partnership with Ionis Pharmaceuticals, provides genetic testing for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that affects motor neurons in the brain and spinal cord. Testing is available to eligible patients in the U.S. and Canada with a clinical diagnosis or family history of ALS. A qualified healthcare provider must order the test.

• Individuals in the U.S. or Canada with a clinical or suspected diagnosis of amyotrophic lateral sclerosis (ALS).
• Pre-symptomatic individuals with a known family history of ALS (age ≥18).
• Symptomatic patients under 18 may be tested if clinical features are documented on the order.
• Exceptions may be considered for known familial, adolescent, or pediatric forms of rapidly progressive ALS.

1. 1

   Discuss Testing With Your Provider

   Your provider will confirm eligibility and explain the test. Pre-test genetic counseling through Genome Medical is available at no cost.

2. 2

   Test Is Ordered

   Your provider will order the test using the appropriate requisition form.

3. 3

   Provide a Sample

   Provide a blood, saliva, or buccal sample. Blood may require an ice pack for shipping; saliva and buccal kits ship at room temperature.

4. 4

   Receive Your Results

   Results are sent to your provider in about 18 days. Your provider will discuss them with you, and post-test counseling through Genome Medical is available.